Abstract:
BACKGROUND:The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD. OBJECTIVE:To evaluate the efficacy and tolerability of budesonide/formoterol administered via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) in patients with COPD. METHODS:This was a 6-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre study (NCT00206154) of 1704 patients aged > or =40 years with moderate to very severe COPD conducted in 194 centres in the US, Czech Republic, the Netherlands, Poland and South Africa. After 2 weeks of treatment based on previous therapy (ICSs and short-acting bronchodilators allowed during the run-in period), patients received one of the following treatments administered twice daily: budesonide/formoterol pMDI 160/4.5 microg x two inhalations (320/9 microg); budesonide/formoterol pMDI 80/4.5 microg x two inhalations (160/9 microg); budesonide pMDI 160 microg x two inhalations (320 microg) plus formoterol DPI 4.5 microg x two inhalations (9 microg); budesonide pMDI 160 microg x two inhalations (320 microg); formoterol DPI 4.5 microg x two inhalations (9 microg); or placebo. MAIN OUTCOME MEASURES:The co-primary efficacy variables were pre-dose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1). RESULTS:Budesonide/formoterol 320/9 microg demonstrated significantly greater improvements in pre-dose FEV(1) versus formoterol (p = 0.026; pre-specified primary comparator) and 1-hour post-dose FEV(1) versus budesonide (p < 0.001; pre-specified primary comparator); budesonide/formoterol 160/9 microg demonstrated significantly greater improvements versus budesonide (p < 0.001) for 1-hour post-dose FEV(1) but not versus formoterol for pre-dose FEV(1). Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score) were significantly improved with both dosage strengths of budesonide/formoterol compared with budesonide, formoterol and placebo (p < or = 0.044 for all). Although not powered a priori for comparisons, the number of exacerbations per patient-treatment year requiring treatment with oral corticosteroids and/or hospitalization was numerically (20-25%) lower with the budesonide-containing treatments (0.710-0.884) versus formoterol (1.098) and placebo (1.110). This result was driven by the exacerbations requiring treatment with oral corticosteroids (79-120 events). The number of exacerbations resulting in hospitalization was very low across treatment groups (11-22); the number per patient-treatment year was significantly different for budesonide/formoterol 320/9 microg (0.158) versus other treatment groups (0.081-0.108) except budesonide/formoterol 160/9 microg (0.139), and for budesonide/formoterol 160/9 microg versus formoterol (0.081) [p < or = 0.05]. All treatments were generally well tolerated. The incidence of individual non-fatal serious adverse events was similar across all treatment groups, except COPD, which was highest in the budesonide/formoterol 320/9 microg group (6.1%) and lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of 4.3-4.6% in the budesonide/formoterol 160/9 microg, budesonide plus formoterol and placebo groups. Budesonide/formoterol had a safety profile comparable with that of the monocomponents and placebo. There was no increase in the incidence of pneumonia in the active treatment groups relative to placebo. CONCLUSIONS:Budesonide/formoterol pMDI 320/9 microg demonstrated significantly greater efficacy for pulmonary function on both co-primary endpoints versus the pre-specified comparators (formoterol DPI 9 microg for pre-dose FEV(1) and budesonide pMDI 320 microg for 1-hour post-dose FEV(1)). Budesonide/formoterol pMDI 160/9 microg demonstrated significantly greater efficacy for 1-hour post-dose FEV(1) versus budesonide pMDI 320 microg. Dyspnoea scores and HR-QOL were significantly improved with both budesonide/formoterol pMDI dosage strengths versus both monocomponents and placebo. Both budesonide/formoterol pMDI dosage strengths were well tolerated relative to the monocomponents and placebo.
journal_name
Drugsjournal_title
Drugsauthors
Tashkin DP,Rennard SI,Martin P,Ramachandran S,Martin UJ,Silkoff PE,Goldman Mdoi
10.2165/00003495-200868140-00004subject
Has Abstractpub_date
2008-01-01 00:00:00pages
1975-2000issue
14eissn
0012-6667issn
1179-1950pii
68144journal_volume
68pub_type
杂志文章,多中心研究,随机对照试验相关文献
DRUGS文献大全abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632890-000000000-00000
更新日期:2012-05-07 00:00:00
abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666170-00001
更新日期:2006-01-01 00:00:00
abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0033-3
更新日期:2013-03-01 00:00:00
abstract::Discharge from the ear can be the result of many disease processes. The ear may discharge blood, pus, cerebrospinal fluid (CSF) or wax. Keratosis obturans, stenosis of the external meatus and benign tumours of the external meatus all lead to wax build-up, which may cause recurrent attacks of otitis externa. Malignant ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243020-00008
更新日期:1992-02-01 00:00:00
abstract::Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200059020-00016
更新日期:2000-02-01 00:00:00
abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01215-9
更新日期:2019-11-01 00:00:00
abstract::Epizoonoses such as scabies, lice and cimicosis are common, vexing disorders that occur worldwide. Historically, many treatment modalities have been employed in the management of these disorders, and most of the drugs described in this review are of historical interest and no longer recommended or in widespread use be...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161080-00004
更新日期:2001-01-01 00:00:00
abstract::Acamprosate (calcium acetylhomotaurinate), a synthetic compound with a similar chemical structure to that of gamma-aminobutyric acid, is thought to act via several mechanisms affecting multiple neurotransmitter systems; inhibition of neuronal hyperexcitability by antagonism of excitatory amino acid activity and reduct...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753060-00008
更新日期:1997-06-01 00:00:00
abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918050-00001
更新日期:1979-11-01 00:00:00
abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500492-00012
更新日期:1995-01-01 00:00:00
abstract::Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0576-1
更新日期:2016-05-01 00:00:00
abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0565-4
更新日期:2016-04-01 00:00:00
abstract::Intravenous inotuzumab ozogamicin (Besponsa®; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0802-5
更新日期:2017-09-01 00:00:00
abstract::Depression is associated with a risk of suicide 13 to 30 times greater than in the general population, and antidepressants are among the drugs most frequently implicated in fatal overdose, resulting in a dilemma for the clinician. Suicidal thoughts are a core symptom of depression, and there is evidence that the selec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200432-00005
更新日期:1992-01-01 00:00:00
abstract::An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01201-1
更新日期:2019-10-01 00:00:00
abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00011
更新日期:2006-01-01 00:00:00
abstract::Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0597-9
更新日期:2016-07-01 00:00:00
abstract::Lung function can be reduced not only by a non-selective beta-blocker but also by a selective beta1-receptor blocker. If both types of drug are without intrinsic sympathomimetic activity, the effect of the non-selective drug is more pronounced than that of a beta1-receptor selective drug under basal conditions. The ef...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-197600111-00035
更新日期:1976-01-01 00:00:00
abstract::The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0376-z
更新日期:2015-04-01 00:00:00
abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161020-00007
更新日期:2001-01-01 00:00:00
abstract::Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furtherm...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11315560-000000000-00000
更新日期:2009-01-01 00:00:00
abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198938020-00009
更新日期:1989-08-01 00:00:00
abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700331-00007
更新日期:1987-01-01 00:00:00
abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198500295-00042
更新日期:1985-01-01 00:00:00
abstract::Although vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions, they are not a homogeneous cell type. Myosin has been used as a marker of SMC differentiation in order to identify distinct SMC populations in the adult rabbit aorta. The medial layer of the normal adult aorta c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400481-00003
更新日期:1994-01-01 00:00:00
abstract::Temocillin is a novel injectable beta-lactam antibiotic designed for parenteral use. It is active against the majority of Gram-negative bacteria and is stable to a wide range of beta-lactamases. Disposition and metabolic studies on temocillin in animals and man demonstrate that the drug is well distributed throughout ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198500295-00021
更新日期:1985-01-01 00:00:00
abstract::Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197510040-00001
更新日期:1975-01-01 00:00:00
abstract::Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767180-00006
更新日期:2007-01-01 00:00:00
abstract::The rationale for the use of nifedipine in patients with acute myocardial infarction (MI) is based on the various cardiovascular actions of the compound: reduction of myocardial oxygen consumption by attenuation of cardiac and vascular smooth muscle tension; augmentation of oxygen and substrate supply after increased ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验,评审
doi:10.2165/00003495-199100422-00007
更新日期:1991-01-01 00:00:00
abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199000394-00004
更新日期:1990-01-01 00:00:00